OvaScience and Active Biotech name new CEOs, Valeant adds John Paulson to the board
→ OvaScience struggled hard last year, dropping its CEO, COO and 30% of its staff. Now they have named a new CEO, Christopher Kroeger. Kroeger previously spent over a decade at the venture firm The Aurora Funds, and before that he ran Cardioxyl, which was sold to Bristol-Myers in 2015 for its heart failure drug. Co-founder and Chairman Michelle Dipp, who stepped in to helm the company during its turbulence, is now taking an advisory role with the fertility company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.